For laboratory research use only. Not for human or veterinary use.

Same-day dispatch on orders before 4 PM ET · Support

Thymosin alpha-1: origin, structure and research history

Research Library › Bioregulators & Thymic

Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminus, first isolated and sequenced in 1977 by Allan Goldstein’s group from thymosin fraction 5, a calf-thymus extract. Its synthetic form, thymalfasin, was marketed abroad as Zadaxin by SciClone Pharmaceuticals. As of 22 Oct 2026 it is not FDA-approved, and FDA advisers voted 17-4 in December 2024 against adding it to the compounding bulks list.

Key facts

Type28-amino-acid peptide, N-terminally acetylated
Derived fromThymosin fraction 5, a partially purified calf-thymus extract
First described1977, Proceedings of the National Academy of Sciences
Developed byAllan Goldstein and colleagues; patent assigned to the University of Texas and Hoffmann-La Roche
Proposed targetT-cell maturation and innate immune signaling, including Toll-like receptors
Regulatory status (Oct 2026)Not FDA-approved; approved in some countries, including China and Italy, as thymalfasin (Zadaxin)

Who developed it

The story begins in 1966, when Allan Goldstein, working with biochemist Abraham White, prepared a thymus extract and named its active factor “thymosin” [1]. A decade later Goldstein’s team purified one component of that extract and determined its amino acid sequence, publishing the result in 1977 as thymosin alpha-1 [2].

The peptide was patented with the University of Texas System and Hoffmann-La Roche as assignees; the U.S. patent was granted in March 1978 [3]. SciClone Pharmaceuticals of California licensed it in 1994 and developed the synthetic version, thymalfasin, under the brand Zadaxin [4].

Structure and proposed target

Thymosin fraction 5 contains more than 30 distinct peptides; alpha-1 is the one that was carried into drug development [2, 5]. It is 28 amino acids long, and its first residue carries an acetyl group. The drug substance, thymalfasin, is produced by chemical synthesis with the same sequence as the natural peptide [2, 6].

The 1977 paper proposed that the peptide participates in T-cell maturation, the process by which the thymus trains immune T cells. Later literature proposed interactions with immune signaling pathways, including Toll-like receptors. These are proposed mechanisms from laboratory research [2, 7].

Why it was created

Goldstein’s group set out to identify the chemical signals the thymus uses to direct T-cell development. After isolation, the peptide was investigated in research programs on chronic viral hepatitis, certain cancers and infections [6, 7].

Research timeline

  • 1966: Goldstein, Slater and White describe and name “thymosin” [1]
  • 1977: Thymosin alpha-1 isolated and sequenced [2]
  • 1978: U.S. Patent 4,079,127 granted [3]
  • 1994: SciClone licenses the peptide [4]
  • 1997: Zadaxin launched in China [4]
  • 1998: Eight new national approvals received during the year [8]
  • Dec 2024: FDA advisory committee votes 17-4 against compounding use [9]
  • Jan 2025: A 1,106-participant phase 3 trial in sepsis is published in The BMJ [10]

Regulatory status as of October 2026

As of 22 Oct 2026, thymosin alpha-1 is not approved by the FDA for any use. Thymalfasin is approved in a number of other countries, including China and Italy [6].

On 4 Dec 2024, FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 17-4 against adding thymosin alpha-1 to the list of bulk drug substances usable in pharmacy compounding [9]. FDA has also flagged a possible immunogenicity risk for compounded versions on its list of bulk substances that may present significant safety risks [11]. On 14 Oct 2026 FDA sent an interim access policy on compounding certain peptides to the White House for review; its peptide list is not public and the policy is not final [12].

The World Anti-Doping Agency’s 2026 Prohibited List does not name thymosin alpha-1; the related name it does list is thymosin beta-4, a different peptide [13].

Available from Kalibra Labs

Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.

Look up a Certificate of Analysis by lot number →

Frequently asked questions

Who discovered thymosin alpha-1?

Allan Goldstein’s research group isolated and sequenced thymosin alpha-1 in 1977, building on the thymosin extract Goldstein and Abraham White described in 1966.

Is thymosin alpha-1 FDA approved?

No. As of October 2026 it is not FDA-approved, and FDA advisers voted 17-4 against adding it to the compounding list in December 2024.

What is thymalfasin?

Thymalfasin is the drug name for synthetic thymosin alpha-1, sold outside the U.S. under the brand Zadaxin.

Is thymosin alpha-1 the same as thymosin beta-4?

No. They are different peptides from the same thymus extract family; thymosin beta-4 is a separate 43-amino-acid peptide.

What company developed Zadaxin?

SciClone Pharmaceuticals of California licensed thymosin alpha-1 in 1994 and marketed the synthetic version as Zadaxin, first launched in China in 1997.

Sources

  1. Goldstein AL, Slater FD, White A. Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin). Proc Natl Acad Sci USA. 1966. PMID 5230175. Link
  2. Goldstein AL, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci USA. 1977;74(2):725-729. doi:10.1073/pnas.74.2.725. PMID 265536. Link
  3. Goldstein AL, Low TLK, Lai CY, Wang SS (assignees Hoffmann-La Roche; University of Texas System). US Patent 4,079,127, Thymosin alpha 1. Priority 28 Oct 1976; granted 14 Mar 1978. Link
  4. SciClone Pharmaceuticals, Inc. Form 10-K for fiscal year 1997 (filed 1998). U.S. SEC EDGAR. Link
  5. Spektrum Lexikon der Chemie. Thymosin alpha1. Spektrum der Wissenschaft. Link
  6. Hankla E, Li J (FDA CDER). Thymosin alpha-1 (Ta1) related bulk drug substances. Pharmacy Compounding Advisory Committee presentation, 4 Dec 2024. Link
  7. Garaci E. Thymosin alpha1: a historical overview. Ann N Y Acad Sci. 2007;1112:14-20. doi:10.1196/annals.1415.039. PMID 17567941. Link
  8. SciClone receives ZADAXIN marketing approvals in Mexico, Cambodia; eight approvals now received during 1998. Press release, San Mateo, CA, 16 Dec 1998. Link
  9. U.S. FDA. Final summary minutes of the Pharmacy Compounding Advisory Committee meeting, 4 Dec 2024 (approved 21 Feb 2025). Link
  10. Wu J, Pei F, et al. The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025;388:e082583. Link
  11. U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 Apr 2026). Link
  12. Office of Information and Regulatory Affairs (reginfo.gov). HHS/FDA, Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94: received 14 Oct 2026, pending review. Link
  13. World Anti-Doping Agency. 2026 Prohibited List (S2.3 names thymosin-beta4, not thymosin alpha-1). Link

Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.

For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.

0
Your Cart
Empty CartYour cart is emptyReturn to Shop
Scroll to Top